A Promising New Non-Hormonal Menopause Treatment

What Happened

A Phase 2a study of Noema Pharma’s experimental drug Cendifensine (formerly NOE-115) announced on November 6, 2025, shows dramatic reductions in menopausal hot flashes and night sweats.

In the 12-week open-label trial (NOE-PPM-201), menopausal women receiving 30 mg or 60 mg daily reported a mean 92.3% reduction in the number of moderate-to-severe vasomotor symptoms (VMS, i.e. hot flashes) by week 12.

Symptom severity also fell: VMS severity dropped by nearly 60% by week 12 in the study. Importantly, participants described improvements not only in hot flashes but also in associated menopause-related symptoms like mood, fatigue, food cravings, and even modest weight loss.

In an interview with Contemporary OB/GYN, investigator Rebecca Dunsmoor‑Su, MD highlighted that across all tested doses, women experienced clinically meaningful relief — as early as week 4, with continued improvement through week 12.

Why It Matters

For many women, hot flashes and night sweats are among the most disruptive symptoms of menopause, often waking them from sleep, affecting mood, concentration, and overall quality of life. Traditional treatments have included hormone therapy (HT) or neurokinin-3 receptor antagonists — but neither is ideal for every woman.

Cendifensine represents a novel, non-hormonal, broad-spectrum approach, targeting central nervous system pathways including serotonin, norepinephrine, and dopamine — potentially offering relief not just for hot flashes, but for a broader cluster of menopause-related symptoms (mood swings, fatigue, cravings, weight changes).

If further trials confirm safety and effectiveness, this could provide a new and attractive option for women who: cannot or prefer not to use hormones; have mixed symptom burdens; or want a more holistic approach to menopause relief.

What This Means for Women in Perimenopause & Menopause

• Women suffering from frequent, moderate-to-severe hot flashes (or night sweats) may soon have a non-hormonal pill option that delivers strong relief.
  
• Because Cendifensine also showed improvements in mood, fatigue, cravings, and even weight, it could help women whose menopausal symptoms go beyond just VMS — offering a more comprehensive symptom relief package.
  
• For those reluctant or unable to use hormone therapy (past cancer, clot risk, other contraindications), this could represent an important new alternative.
  

Access & Availability

• Currently, Cendifensine is investigational. The 2025 Phase 2a results are promising, but the drug is not yet approved for general use.
  
• The next step will likely be Phase 2b or Phase 3 trials to confirm safety, optimal dosing, and long-term effects.
  
• For now, the drug is only accessible in a research setting — not yet available by prescription or over the counter.
  

Benefits & Risks

Potential Benefits

• Very substantial reduction in hot flash frequency and severity.
  
• Possible additional relief from mood swings, fatigue, cravings, weight changes — addressing more than just VMS.
  
• Non-hormonal mechanism, which may offer benefits for women who cannot (or choose not to) use hormone therapy.
  

Known/Reported Risks & Unknowns

• In the Phase 2a trial, treatment was described as “generally well tolerated.” No serious adverse events were reported.
  
• Because it’s early-stage research, long-term safety, side effects, and effectiveness have not yet been established.
  
• As with any new therapy, optimal dosing and how it interacts with other medications remain to be determined.
  

Next Steps / What to Watch For

• Watch for Phase 2b or Phase 3 trials from Noema Pharma to confirm safety and efficacy.
  
• Monitor for any peer-reviewed publications and larger, placebo-controlled studies (the 2025 trial was open-label).
  
• Once approved, consider how this treatment could fit into individualized menopause plans — especially for those seeking non-hormonal, multi-symptom relief.
  
• Keep an eye on updates from menopause research and regulatory bodies for coverage, guidance, and long-term data.
  

What This Means for Your Midlife Health

Cendifensine’s promising Phase 2a data offers real hope for a new, non-hormonal path to relief — and one that may touch on many of the symptoms that make menopause tough. For women feeling stuck between limited options or wary of hormone therapy, this emerging therapy could broaden choices and restore quality of life. We’ll continue to follow the research so you’re among the first to know when (and if) it becomes widely available.

Further Reading

If you’re curious to dive deeper, check out these resources:

• Noema Pharma press release: Noema Pharma Announces Phase 2a Study Results with Cendifensine in Women with Hot Flashes Due to Menopause
  
• Contemporary OB/GYN: Interview with Dr. Rebecca Dunsmoor-Su highlighting Cendifensine’s phase 2 trial results
  
• BioSpace: Summary of Cendifensine topline results from a Phase 2a Study

What Happened

In November 2025, BWHI published the preliminary findings from the largest national survey ever on menopause and perimenopause in Black women. The survey gathered responses from more than 1,500 Black women across the U.S. (ages 30–65), capturing their lived experiences with symptoms, healthcare, and systemic challenges.

Key headline findings include:

• 52% of respondents said they did not know which medical recommendations to follow during menopause.
  
• 46% reported they lacked adequate information to manage their symptoms.
  
• 43% experienced discrimination or unfair treatment when seeking care for menopause-related issues.
  
• 42% said they struggled with depression during this stage of life.
  

BWHI’s press release describes the survey as a first-of-its-kind effort to highlight the unique experiences of Black women during menopause — a demographic historically underrepresented in menopause research.

Why It Matters

Menopause research and care have often been based on data from predominantly white populations. As a result, the symptoms, cultural context, and systemic barriers faced by Black women have largely remained invisible. This survey challenges that gap, offering data that can inform more equitable care, culturally responsive practices, and targeted support.

The findings suggest that many Black women are navigating menopause without clear guidance, reliable information, or supportive healthcare — even when they are insured and professionally active.

By shedding light on these disparities, the survey could steer future research, influence clinical guidelines, and push for health-care access and education tailored to Black women.

What This Means for Women in Perimenopause & Menopause

If you are a Black woman approaching or going through menopause, this survey validates that your experience — including concerns about symptom management, access to care, and emotional well-being — is real, shared, and deserves attention.

You may find comfort knowing that others have faced similar challenges: unclear medical advice, insufficient information, and even discrimination when seeking care.

Importantly:

• You are not alone. These findings show systemic patterns — not just isolated incidents.
  
• Your voice matters. Sharing your story with your provider can help push for better care that recognizes the intersection of race, gender, and menopause.
  
• Awareness is power. Understanding that many Black women lack access or information could encourage you to seek out supportive providers, patient-advocacy communities, or culturally aware resources.
  

Access & Availability

• The survey is publicly available via BWHI’s “Power in the Pause” initiative. Results (preliminary) can be downloaded from their website.
  
• Because this is a national online survey, data reflects a broad cross-section of insured and insured-women, showing that lack of support isn’t limited to marginalized sub-groups.
  
• Further data, including deeper analysis by age, region, and health status, may be released as BWHI finalizes its review.
  

Benefits & Risks

Strengths:

• Largest national survey of Black women’s menopause experiences — large sample size, broad age range.
  
• Helps fill critical knowledge gaps regarding racial disparities, cultural context, and systemic barriers in menopause care.
  
• Data can inform advocacy, policy, and culturally sensitive care models.
  

Limitations / What to Interpret Carefully:

• Findings are preliminary. As a cross-sectional survey, results reflect self-report and perceptions (not clinical diagnoses).
  
• The survey captures a snapshot in time, not longitudinal experience — so it can’t show how symptoms or care evolve.
  
• Experiences may vary widely depending on socioeconomic status, region, health history — not all subgroups may be represented equally.
  

Next Steps / What to Watch For

• Full data release with detailed breakdowns (by age, region, income, health history) — useful for researchers, clinicians, and advocates.
  
• Increased attention — healthcare providers may begin integrating these findings to offer more culturally responsive menopause care.
  
• Development of targeted resources: education, support groups, culturally attuned guidance, mental-health outreach.
  
• More research — including longitudinal studies — to better understand how menopause impacts Black women over time.
  

What This Means for Your Midlife Health

This survey is more than data — it’s a wake-up call. If you’re a Black woman in midlife: your experiences, concerns, and needs are valid. Healthcare systems need to catch up to what millions have known for decades.

You deserve menopause care that recognizes your identity, cultural background, and unique history. This survey gives you — and the world — a stronger foundation to push for that care.

Further Reading

If you’re curious to dive deeper, check out these resources:

• BWHI Press Release: Preliminary Findings from the Largest National Survey on Black Women’s Menopause Experiences Black Women's Health Imperative
  
• PR Newswire: Black Women's Health Imperative Releases Preliminary Findings from the Largest National Survey on the Lived Experiences of Black Women During Menopause

What Happened

Today, the Food and Drug Administration (FDA) formally requested drug manufacturers to remove the boxed (black-box) warning from certain estrogen-containing therapies used for menopause, signaling a major shift in regulatory stance.

The boxed warning, the strongest label the FDA can apply, has long cautioned of risks such as stroke, blood clots, breast cancer and dementia for hormone therapies used in menopausal women. But new evidence and expert review suggest the warning may no longer accurately reflect current risk profiles.

Why It Matters

For decades, the black box warning has deterred many women—and their doctors—from using hormone therapy (HT), even when it might be beneficial. Modern research shows that risks tied to hormone therapy depend heavily on age at initiation, formulation, delivery method, and timing (particularly within 10 years of menopause). The blanket warning, many experts say, misleads and restricts access to safe care.

Removing or revising the warning could improve access, diffuse long-standing fears, and align labeling with the contemporary evidence—potentially improving care and outcomes for many women.

What This Means for Women in Perimenopause & Menopause

If you’re experiencing menopausal symptoms such as hot flashes, night sweats, vaginal changes, mood shifts or sleep disruption—and you either avoided hormone therapy due to fear of risks or were told you weren’t a candidate—the regulatory shift may open new conversations.

• You may feel more empowered to revisit HT with your healthcare provider—and ask about timing of initiation, formulation, delivery route and personal risk profile.
  
• If you're within 10 years of your last period or under age 60, current data suggest the benefit-risk ratio is more favorable.
  
• Women who avoided low-dose vaginal estrogen or other formulations because of the warning may find renewed options.
  

Access & Availability

Hormone therapy products are already widely available. What’s changing is the labeling and risk-communication framework, not necessarily the drugs themselves. Women may soon see updated labels that clarify risk stratification, timing and formulations. Over time, physicians may become more comfortable prescribing—and insurers may adjust coverage practices.

Benefits & Risks

Benefits

• More accurate risk communication aligned with modern evidence.
  
• Increased confidence among women and prescribers.
  
• Potential increase in appropriate use of HT when indicated, improving symptom relief and health outcomes.
  

Risks / Considerations

• Not all HT should be approached as “risk-free”: systemic therapies for older women (> 60 yrs) or those starting many years post-menopause may still carry elevated risk.
  
• Patients must still individualize decisions with their provider, considering personal history (e.g., breast cancer, stroke, clotting disorders).
  
• The regulatory process is ongoing—changes may not be instantaneous, and labeling may evolve gradually.
  

Next Steps / What to Watch For

• Watch for formal FDA guidance, updated product labels, and manufacturer communications.
  
• Monitor major menopause societies (e.g., The North American Menopause Society) and health organizations for updated guidance.
  
• Observe whether prescribing rates of appropriately timed HT increase and whether outcomes improve in perimenopausal and early-menopausal women.
  
• Keep an eye on insurance coverage and provider education—change in labeling is only one part of wider care evolution.
  

What This Means for Your Midlife Health

This development signals a potential turning point in menopause care. It suggests the era of blanket “one-size-fits-all” risk messaging may be giving way to nuanced, individualized treatment decisions.

If you’ve delayed hormone therapy out of fear or were told you weren’t eligible, now may be the time to revisit the conversation with your provider. Your midlife health—and quality of life—deserves clarity, confidence, and options aligned with you.

Further Reading

If you’re curious to dive deeper, check out these resources:

• CBS News HealthWatch
• Science News
• Women's Health

What Happened

On October 27, 2025, the Elinzanetant (brand name Lynkuet) received approval from the U.S. Food & Drug Administration (FDA) as a non-hormonal pill designed to treat moderate to severe hot flashes associated with menopause. Developed by Bayer, this new therapy works by targeting NK-1 and NK-3 receptors—brain pathways linked to temperature regulation. Clinical trials showed that women taking Lynkuet saw about a 55% reduction in hot-flash frequency after 12 weeks compared with a placebo.

Why It Matters

Hot flashes and night sweats are among the most common—and disruptive—symptoms of menopause. Until now, symptom relief has largely involved hormone therapy (HT), which isn’t safe or suitable for everyone (for example, women with past hormone-sensitive cancer). Lynkuet offers a hormone-free alternative, broadening the treatment options for women. It represents a significant shift in how menopause care can be tailored.

What This Means for Women in Perimenopause & Menopause

If you’re dealing with frequent hot flashes that interfere with sleep, concentration, or comfort—especially if hormone therapy isn’t an option—this new drug may be relevant for you. Because Lynkuet is non-hormonal, it fills a treatment gap for women who:

• Cannot or choose not to use estrogen-based therapies.
  
• Have tried other non-hormonal options with limited success.
  
• Are looking for therapies designed specifically for menopause rather than repurposed medications.
  

Access & Availability

Lynkuet will be available by prescription in U.S. pharmacies starting in November 2025. Bayer has indicated the list price at around $625 per month, though insured patients may pay as little as $25 via savings programs. Availability in other countries or markets will depend on regulatory approvals and rollout strategy by Bayer.

Benefits & Risks

Benefits:

• Significant reduction in hot-flash frequency and severity.
  
• Improvements in sleep and restfulness reported in trial participants.
  
• Non-hormonal mechanism makes it an important option for many women.
  

Risks & Considerations:

• Some participants experienced elevated liver enzyme levels (possible early liver injury); as a result, the FDA recommends baseline and 3-month liver monitoring.
  
• Common side effects included tiredness, headache, and sleepiness.
  
• Long-term safety beyond one year and use in women with certain health conditions are still being monitored.
  

Next Steps / What to Watch For

• Post-approval real-world data will help clarify how Lynkuet performs outside of clinical trials.
  
• Research on how Lynkuet compares to other non-hormonal therapies and how it integrates with broader menopause care will be important.
  
• Watch for updates in prescribing guidelines and insurance coverage, plus any safety alerts or label changes.
  
• International availability—whether Lynkuet will be approved in other countries and how quickly—will matter for global access.
  

What This Means for Your Midlife Health

This approval marks a meaningful advance in menopause care. For women who have struggled with hot flashes and either cannot use hormone therapy or prefer a non-hormonal route, Lynkuet offers new hope. It underscores an important message: you deserve relief, and treatment options are evolving. We’ll continue to track this development so you’re among the first to know when full availability, cost-details, and long-term outcomes are clarified.

Further Reading

If you’re curious to dive deeper, check out these resources:

• CBS News HealthWatch
  
• Lynkuet (elinzanetant) official site

Dydrogesterone-Only HRT Returns After 17 Years, Offering Predictable Bleeding Patterns and Enhanced Endometrial Protection

What Happened

Gedeon Richter UK has launched Nalvee (10 mg dydrogesterone)—a progestogen-only tablet—marking the return of a dydrogesterone-only formulation for hormone replacement therapy (HRT) after a 17-year absence in the UK.

Nalvee is offered to clinicians as an option for non-hysterectomised women on estrogen therapy, intended to protect the endometrium without requiring combined progestogens or higher doses.

This product is a branded generic of a formulation first introduced in 1961, previously withdrawn from the UK market in 2008 due to declining HRT use.

Why It Matters

Progestogens are essential in HRT regimens to protect the uterine lining (endometrium) when estrogen is used in women who still have a uterus. The reintroduction of a dydrogesterone-only option gives prescribers and women more flexibility in tailoring hormonal therapy.

Dydrogesterone is believed to mimic natural progesterone more closely than some synthetic progestogens and is highly bioavailable. The 10 mg dose reportedly provides endometrial protection in 97% of women.

One of the common reasons women discontinue HRT is unpredictable or heavy bleeding. Clinicians believe Nalvee’s more favorable, predictable bleeding profile may improve adherence and satisfaction.

What This Means for Women in Perimenopause & Menopause

For women receiving estrogen therapy who still have a uterus, the availability of a progestogen-only option like Nalvee can influence decisions about which HRT regimen to use.

If you’ve avoided or discontinued HRT because of side effects from progestogens (such as mood symptoms, bloating, or irregular bleeding), Nalvee may offer a gentler alternative—though individual response will vary.

Because this is a UK launch, U.S. women won’t yet have direct access—but this development signals broader momentum in refining HRT options globally, which could eventually influence international offerings.

Access & Availability

• UK: Nalvee is now launched in the UK market.
• Other Countries: The product remains available elsewhere, but its return in the UK is significant given its prior absence.
• Prescription: It is intended for use in combination with estrogen in non-hysterectomised women.

Benefits & Risks

Benefits

• Offers a progestogen-only HRT option, without needing more complex or synthetic progestogens.
• Dydrogesterone is bioavailable and designed to act at low doses, potentially reducing side effects.
• Its predictable bleeding profile may reduce the disruptive irregular bleeding that leads many women to stop HRT.

Risks & Considerations

• As with all hormonal treatments, individual risks depend on health history (e.g. breast cancer risk, cardiovascular risk).
• Even though the safety profile is well established from historical use, updated long-term safety data in modern HRT contexts may still be needed.
• Not all women metabolize progestogens similarly; what is tolerable for one may not be for another.

Next Steps / What to Watch For

• Monitoring real-world data and post-marketing safety in the UK to confirm tolerability and adherence benefits.
• Comparative studies between Nalvee and other progestogens (e.g. micronized progesterone, synthetic progestins) on side effects, bleeding, and patient satisfaction.
• Regulatory consideration in other markets—will this formulation be introduced outside the UK?
• Guidance from menopause societies and HRT protocols on when and how best to use Nalvee.

What This Means for Your Midlife Health

The re-entry of a dydrogesterone-only progestogen offers a welcome expansion in HRT options, reinforcing that hormone therapy is not one-size-fits-all. For women in midlife considering or using HRT, this means more room for personalized care—for better balance between benefits and side effects.

Further Reading

If you’re curious to dive deeper, check out:

PharmaTimes: Gedeon Richter Launches Nalvee in UK to Expand HRT Options for Menopause

New Data Shows Year-Long Relief from Hot Flashes and Improved Sleep, But Some Answers Still Pending

What Happened

A major Phase 3 randomized clinical trial (OASIS-3), published September 8, 2025 in JAMA Internal Medicine, has provided extended data on elinzanetant for treating moderate to severe vasomotor symptoms (VMS), i.e. hot flashes, in postmenopausal women.

In the trial, over 600 women (aged ~40-65) were randomized to once-daily oral 120 mg elinzanetant or placebo for 52 weeks. The primary outcome: change in frequency of moderate to severe hot flashes at 12 weeks. Secondary/exploratory outcomes included hot flash severity, sleep disturbance, and quality of life over 50-52 weeks.

Key findings:

• At week 12, women taking elinzanetant saw a significantly greater reduction in daily moderate to severe VMS frequency vs placebo (mean reduction ~5.4 vs ~3.5 per day).
• These improvements in hot flash frequency and severity were sustained out to week 50.
• There were also improvements in sleep disturbance scores and menopause-related quality of life, though the trial was not powered to prove statistical significance on those secondary endpoints.

Safety findings: no evidence of hepatotoxicity (liver damage) or endometrial hyperplasia; bone density and markers were stable; there were more treatment-related adverse events than placebo (e.g. somnolence, fatigue, headache).

Why It Matters

This 52-week trial strengthens evidence for elinzanetant by providing longer-term data. Earlier trials (OASIS-1 and OASIS-2) were shorter in duration; OASIS-3 shows sustained benefit over a full year. That’s important because menopausal symptoms (especially hot flashes and sleep disturbance) often last many years.

More robust safety data over a year helps clinicians and women better weigh risks vs benefits—particularly for non-hormonal options. Also, the lack of requirement for a minimum number of hot flashes per week in some enrollment criteria makes the results more relevant to a broader group of women, not just those with extremely frequent symptoms.

What This Means for Women in Perimenopause & Menopause

If you read our earlier article, Elinzanetant Under FDA Review as a Potential New Option for Menopausal Symptoms, this new trial gives you more detail on how it might perform over the long haul.

For women experiencing hot flashes:

• You may see relief in symptom frequency and severity within 12 weeks.
• Improvements in sleep may follow, though the evidence is “descriptive” for now.
• Even beyond that, benefits appear to sustain over nearly a full year.

For women who can’t or prefer not to use hormones, elinzanetant is looking increasingly promising as a non-hormonal option.

Access & Availability

• The drug remains under FDA review; this trial adds strong evidence but is not yet an approval guarantee.
• Many of the trial sites were in North America and Europe, so it’s relevant to Western markets, though regulatory timing will vary.

Benefits & Risks

Benefits

• Significant and sustained reduction of hot flashes (moderate to severe).
• Potential improvements in sleep and quality of life.
• Non-hormonal mechanism—important for women with contraindications to hormone therapy.

Risks and Other Considerations

• Higher rate of treatment-related adverse events compared to placebo (somnolence, fatigue, headache).
• Some lab value changes (liver enzymes in few women) but no strong signal of serious liver injury in this trial.
• Not yet enough data for women with certain preexisting conditions (e.g. recent cancer) or for representation across all ethnic groups.

Next Steps / What to Watch For

• FDA’s decision and labeling, once approved, will need to include long-term safety guidance.
• Watch for post-approval studies and real-world evidence to confirm the trial findings.
• Side effect monitoring, especially for sleep disruptions, fatigue, or neurological symptoms.
• Data from subgroups (older postmenopausal women, those with comorbidities) to see how broadly applicable benefits are.

What This Means for Your Midlife Health

This latest trial gives stronger reasons for optimism. The growing data suggest elinzanetant is not just a hopeful experimental option but one that may become a practical, long-term tool in menopause symptom management—especially for hot flashes and sleep disruption. As regulatory decisions occur, you’ll be among those who have detailed, up-to-date info for conversations with your healthcare provider.

Further Reading

If you’re curious to dive deeper, check out these resources:

• Elinzanetant: The 52-Week OASIS-3 Phase 3 Trial
• Earlier Article: Elinzanetant as a Non-Hormonal Hot Flash Treatment (MenoHello)

AndroFeme Becomes First Licensed Testosterone Cream for Women's Sexual Health in the UK

What Happened

On August 12, 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved AndroFeme® Cream 10mg/ml, the first testosterone cream specifically licensed for postmenopausal women. This treatment is designed for hypoactive sexual desire dysfunction (HSDD), a condition marked by persistent and distressing loss of libido that affects an estimated 6–13% of women in Europe. Until now, women in the UK had no licensed testosterone option; doctors often prescribed male-strength products “off-label.” AndroFeme® is a body-identical hormone, already available in Australia, New Zealand, and South Africa (as TestaFeme®).

Why It Matters

This approval is a major step forward in menopause care. For years, women relied on testosterone products made for men, which made accurate dosing difficult and sometimes increased side-effect risks. Having a treatment designed for women means safer, more precise, and more regulated care. It also signals growing recognition of testosterone’s important role in women’s health—particularly in quality of life and sexual wellbeing.

What This Means for Women in Perimenopause & Menopause

For women struggling with low libido during menopause or perimenopause, AndroFeme® offers a long-awaited, tailored solution. According to UK guidance from NICE, testosterone can already be considered for women with low sexual desire when HRT alone is not effective.

Beyond sexual health, research suggests testosterone therapy may also help with:

• Energy: Reducing menopause-related fatigue.
• Cognitive function: Improving memory and mental clarity (“brain fog”).
• Muscle and bone health: Supporting strength and bone density, helping reduce osteoporosis risk.
• Mood: Easing low mood, irritability, and anxiety.

These additional benefits are not yet formally included in UK guidelines, but the approval of a licensed product may encourage further research and broader medical discussion.

Access & Availability

AndroFeme® has been approved in the UK, but its launch is expected in 2026. Until then, women may still need to access it through private clinics under a special import license.

Benefits & Risks

• Main benefit: Improved libido and sexual satisfaction for women with HSDD.
• Other potential benefits: Energy, mood, and cognitive improvements.
• Risks: Side effects are usually mild and dose-related (slight increase in body hair, oily skin, or acne). Rarely, higher doses can cause hair thinning or voice deepening. As with all topical creams, there’s a small risk of transferring the product to others, so handwashing and covering the application site are advised.

Next Steps / What to Watch For

The key milestone is the 2026 launch in the UK. It will be important to see whether the NHS makes AndroFeme® widely available and whether prescribing guidelines (such as NICE) are updated to reflect testosterone’s potential wider benefits for menopause care.

What This Means for Your Midlife Health

The approval of a licensed, female-specific testosterone cream is a milestone in women’s health. It represents progress toward more precise, regulated, and respectful treatment options for menopause symptoms. For women in the US and elsewhere, this decision is also a hopeful sign that regulatory agencies worldwide may follow the UK’s lead. We’ll continue to track developments so you’ll know when—and how—treatments like this become available.

Further Reading

If you’re curious to dive deeper, check out these resources:

• Lawley Pharmaceuticals Announcement
• Menopause Care: Everything You Need to Know About AndroFeme

The Hormone-Free Hot Flash Solution

What Happened

Bayer’s elinzanetant (brand name Lynkuet) is a new, non-hormonal therapy designed to reduce moderate to severe hot flashes in menopausal women. The drug works by targeting NK-1 and NK-3 receptors, which play a role in regulating body temperature and vasomotor symptoms.

Late-stage clinical trials have shown promising results, with participants reporting meaningful reductions in hot flash frequency and severity.

Currently, the FDA has extended its review of elinzanetant by up to 90 days. This administrative extension does not suggest safety concerns; it is part of the normal review process for new medications.

Why It Matters

For many women, hormone therapy (HT) is not an option due to health risks, personal preference, or contraindications. Elinzanetant represents another non-hormonal approach to managing hot flashes, adding to the growing range of treatment options.

This potential therapy is especially significant because non-hormonal alternatives have historically been limited and less effective, leaving many women without satisfactory relief.

What This Means for Women in Perimenopause & Menopause

If approved, elinzanetant could offer relief to women who:

• Cannot take estrogen-based treatments due to medical contraindications.
• Prefer a non-hormonal solution.
• Struggle with disruptive hot flashes that interfere with sleep, work, or daily life.

While the drug is still under review, it’s important for women to stay informed about emerging options and discuss symptom management with their healthcare providers.

Access & Availability

• U.S.: Under FDA review; approval decision pending.
• International: No approvals yet; future regulatory filings may follow depending on FDA outcome.

Benefits & Risks

Potential Benefits

• Reduction in frequency and severity of hot flashes.
• Non-hormonal mechanism, suitable for women who cannot use hormone therapy.
• May improve sleep quality and overall quality of life.

Potential Risks / Considerations

• Long-term safety data is limited since it is a new medication.
• Possible side effects will be clarified once FDA review is complete and labeling is finalized.

Next Steps / What to Watch For

• FDA decision expected after the extended review period.
• Monitoring of trial data and post-approval safety will guide real-world use.
• If approved, doctors will begin integrating elinzanetant into non-hormonal menopause treatment strategies.

What This Means for Your Midlife Health

Elinzanetant represents a hopeful step forward for women seeking safe, effective, non-hormonal solutions for hot flashes. While still under review, staying informed allows women to make empowered choices about future treatment options.

Further Reading

If you’re curious to dive deeper, check out these resources:

• Bayer Press Release on Elinzanetant
• Clinical Trial Results: Elinzanetant for Menopausal Hot Flashes

Doctors Push to Remove Warning That Scares Women Away From Safe, Effective Treatment for Menopause Symptoms

What Happened

In July 2025, an FDA-convened panel of medical experts heard testimony urging the removal of the “black box warning” from low-dose vaginal estrogen therapies. The boxed warning—first applied in 2003—was originally meant to highlight serious risks linked to systemic estrogen. But over the past 22 years, research has shown that these warnings don’t apply to tiny, localized doses of vaginal estrogen.

Experts say the outdated label is misleading, harms patients, and keeps women from using an effective treatment for genitourinary symptoms of menopause (GSM).

Why it Matters

Since 2003, the FDA has required all estrogen products to carry the same boxed warning—no matter the dosage, delivery method, or even whether the estrogen is synthetic or bioidentical.

That means a high-dose, whole-body estrogen patch and a pea-sized vaginal cream with almost immeasurable systemic absorption carry the same alarmist warning. The result? Confusion, fear, and avoidance.

Many doctors prescribe low-dose vaginal estrogen, but patients often refuse treatment once they read the insert. And that hesitation comes with a steep cost in both quality of life and long-term health.

What This Means for Women in Perimenopause & Menopause: The Real Impact of GSM

This isn’t about “just a little dryness.” Genitourinary Syndrome of Menopause (GSM) is a chronic, progressive condition affecting 50%–90% of postmenopausal women. Symptoms include:

• Vaginal pain and burning
• Painful sex
• Urinary urgency and frequency
• Recurrent urinary tract infections (UTIs)

These aren’t minor issues. UTIs send thousands of women to the hospital every year and account for significant Medicare spending. Research shows that low-dose vaginal estrogen can prevent UTIs, reduce suffering, save lives, and cut healthcare costs.

The Problem With the Warning

The boxed warning implies that all estrogen products—whether systemic or local—carry risks of stroke, blood clots, or dementia. But here’s the truth:

• Low-dose vaginal estrogen does not significantly raise blood estrogen levels.
• There is no evidence linking it to those serious conditions.
• Scientific evidence supports its safety and effectiveness.

The mismatch between evidence and policy creates fear where none is warranted. Women are avoiding intimacy because of pain, skipping exercise classes because of discomfort, and isolating themselves socially—all while a safe treatment sits unused.

What’s at Stake

The panel’s July hearing underscored that the box is harming women and misinforming patients. As one expert framed it: women are dying from UTIs, not strokes caused by vaginal estrogen. Yet the boxed label continues to reinforce misplaced fears.

Behind the policy are real lives:

• Women who can’t wear yoga pants because of pain.
• Women who don’t go to the movies because they’d need the bathroom every five minutes.
• Women who avoid intimacy despite having a safe treatment option.

What’s Next

The FDA now faces a pivotal decision. Will it modernize its labeling policy and align with the science? Or will the black box warning continue to stand as a barrier to safe, effective care?

Many experts are hopeful that change is finally coming. Removing the boxed warning could open the door to wider use of a therapy that has been unfairly stigmatized for over 20 years.

Further Reading

If you’re curious to dive deeper, check out these resources:

• Harvard Health: Understanding Hormone Therapy for Menopausal Symptoms
• Vaginal Estrogen Use and Chronic Disease Risk in the Nurses’ Health Study

Fezolinetant Offers Relief from Moderate to Severe Hot Flashes — With Mandatory Liver Monitoring Protocol

What Happened

In May 2023, the U.S. Food and Drug Administration (FDA) approved fezolinetant (brand name Veozah), the first non-hormonal medication in a new class called NK₃ receptor antagonists. It’s designed specifically to reduce moderate to severe hot flashes in menopausal women. The European Union followed with its own approval in December 2023, marking a global shift in treatment options.

However, in September 2024, the FDA issued a new safety warning after reports of rare but serious cases of liver injury among users, prompting updated guidance for monitoring.

Why It Matters

For decades, hormone therapy (HT) has been the most effective option for managing hot flashes, but not every woman can—or wants to—take hormones. Fezolinetant represents a breakthrough by offering a non-hormonal alternative backed by clinical trial data, signaling progress toward personalized menopause care.

Still, the added liver safety warning reminds both doctors and patients that no treatment is risk-free, and ongoing vigilance is essential.

What This Means for Women in Perimenopause & Menopause

If hot flashes are disrupting your sleep, mood, or daily life—and you can’t or prefer not to take hormones—fezolinetant may provide an option. Many women report meaningful relief within weeks.

But, because of the liver injury warning, doctors now recommend baseline and ongoing liver function tests while taking the drug. This means that women who choose this therapy should expect regular blood work and monitoring.

Access & Availability

• U.S.: FDA-approved in May 2023; available by prescription.
• EU: Approved in December 2023.
• Other regions: Still under regulatory review in some countries.

Benefits & Risks

Benefits

• Significantly reduces the frequency and severity of hot flashes.
• Works without hormones, making it a viable option for women who cannot take estrogen.
• May improve sleep and overall quality of life by easing disruptive symptoms.

Risks

• Rare but serious liver injury (requires ongoing monitoring).
• Common side effects reported: headache, abdominal pain, diarrhea, and insomnia.
• Limited long-term safety data compared to established hormone therapies.

Next Steps / What to Watch For

• Post-market safety data will shape how widely fezolinetant is prescribed.
• Researchers are studying whether similar non-hormonal drugs could expand treatment options.
• The FDA and EMA may issue updated guidance as more safety information emerges.

What This Means for Your Midlife Health

Fezolinetant signals hope for women who want more non-hormonal solutions for menopause care. It’s proof that research is expanding beyond hormones, but it also highlights why careful, informed decision-making with your doctor is so important. As more data comes in, you’ll know whether this medication—or future ones in its class—could be right for you.

Further Reading

If you’re curious to dive deeper, check out these resources:

• FDA Announcement on Fezolinetant Approval (Veozah)
• FDA Safety Warning on Liver Risks

20-Year Follow-Up of 160,000 Women Shows Benefits Outweigh Risks When Started Within 10 Years of Menopause

What Happened

A wave of new research, including a landmark 2024 review of the Women’s Health Initiative (WHI), has transformed how doctors view hormone therapy (HT) for menopause. The findings show that for healthy women under age 60, or within 10 years of menopause, starting HT early can provide significant benefits that outweigh the risks. Unlike the widely publicized 2002 WHI results—which linked HT to breast cancer and heart disease—this updated evidence clarifies that risks depend on factors like age, type of hormone, and delivery method.

Why It Matters

For two decades, fear from the original WHI findings left millions of women without access to therapies that could have improved their quality of life. Many physicians became reluctant to prescribe HT, and women often avoided it due to concern over serious risks. This shift in understanding means the conversation around HT can finally be more nuanced, individualized, and hopeful.

What This Means for Women in Perimenopause & Menopause

If you’re experiencing hot flashes, night sweats, sleep disruption, or bone loss, and you’re under 60 or within 10 years of your final period, HT may be a safe and effective option. The updated science supports a more personalized approach, considering your age, health history, and whether you use estrogen alone or in combination with progesterone.

Access & Availability

HT is widely available in the U.S. and globally, but prescribing practices vary. Some doctors may still rely on outdated WHI concerns. If you’re interested, it’s worth bringing this new evidence to your provider and asking whether HT could fit your needs.

Benefits & Risks

Potential Benefits

• Relief from hot flashes and night sweats
• Improved sleep and mood
• Protection against bone loss and fractures
• Possible reduced risk of colon cancer and type 2 diabetes

Potential Risks

• Risk profiles vary depending on age, type of hormone, and delivery method
• Risks increase for women who start HT later in life or who have certain health conditions
• Breast cancer risk appears to be linked more strongly to combined estrogen-progestin therapy than to estrogen-only therapy

Next Steps / What to Watch For

More research is underway to refine HT recommendations, including studies on bioidentical hormones, transdermal patches, and lower-dose therapies. Expect to see updated guidelines from leading organizations like the North American Menopause Society (NAMS) and possibly revised public health messaging to better reflect the evidence.

What This Means for Your Midlife Health

The past 20 years of fear-driven messaging around hormone therapy are finally being corrected. This doesn’t mean HT is right for everyone—but it does mean you have more accurate, individualized information to guide your choices. As research continues, we’ll keep tracking these updates so you can make confident, informed decisions about your health.

Further Reading

• New Study Supports Hormone Replacement Therapy in Early Menopause
• NAMS Statement on Hormone Therapy: Updated Evidence and Recommendations

Pushing Back the Change: Implications for Women's Health and Longevity

What Happened

A groundbreaking pilot study is testing whether rapamycin, a drug originally developed for organ transplant patients, could slow ovarian aging and potentially delay the onset of menopause. Researchers at Columbia University Irving Medical Center are studying the effects of a once-weekly pill to see if it preserves ovarian function in women.

Why It Matters

For decades, menopause was thought to be an unchangeable milestone of life. This research challenges that assumption, raising the possibility of extending fertility, reducing midlife health risks, and transforming how we think about aging in women’s health. If ovarian aging can be slowed, it could not only delay menopause but also protect against conditions linked to estrogen decline, like osteoporosis, cardiovascular disease, and cognitive changes.

What This Means for Women in Perimenopause & Menopause

Even if you’re already in menopause, this line of research is important. It signals that scientists are beginning to prioritize women’s reproductive aging—an area long overlooked in medicine. While the therapy is not yet available, it could someday give future generations of women more options and control over when menopause occurs. For women nearing menopause now, it’s encouraging to know that midlife health is being taken seriously in cutting-edge research.

Access & Availability

Currently, this is an experimental therapy only available in clinical trials. Rapamycin is not approved for delaying menopause, and researchers emphasize that more studies are needed before it could ever become a treatment option for the general public.

Benefits & Risks

• Potential benefits: Preserving ovarian function, extending fertility, delaying menopausal symptoms, and possibly reducing risks of age-related diseases.
• Risks & cautions: Rapamycin suppresses the immune system, which could increase infection risk. Long-term effects in healthy women are unknown, and safety is a major focus of the clinical trials.

Next Steps / What to Watch For

The Columbia University team is continuing its research and monitoring participants closely. Larger, longer-term trials will be needed to confirm whether rapamycin can safely and effectively delay menopause. If the findings hold, this could mark one of the most transformative shifts in women’s health care in decades.

What This Means for Your Midlife Health

While rapamycin is not available as a menopause treatment today, the fact that it’s being studied at all is a hopeful sign that the future of midlife care is evolving. We’ll continue to follow this story closely and keep you informed about any breakthroughs that could eventually impact your options.

Further Reading

• Pilot Study: Can a Weekly Rapamycin Pill Slow Ovarian Aging?
• Columbia Clinical Trial: Exploring the Possibility of Delaying Menopause

The News: Heart Health Declines Rapidly After Menopause

What Happened

A new study presented at the American College of Cardiology’s Annual Scientific Session reveals a sharp and swift decline in women’s heart health immediately following menopause. Researchers, examining data from over 579,000 individuals, found that while men generally face higher rates of cardiovascular disease earlier in life, women experience a rapid acceleration in cardiovascular risk after they stop menstruating, causing their risk profile to quickly catch up to men’s.

This shift highlights menopause as a pivotal period for cardiovascular health. The hormonal changes—especially declining estrogen—may contribute to stiffer blood vessels, unfavorable shifts in cholesterol, and rising blood pressure. These factors combined can significantly elevate a woman’s risk for heart attack, stroke, and other heart-related conditions.

Why It Matters

Heart disease is the leading cause of death for women in the U.S. and globally. Despite this, women often underestimate their personal risk, or they may find their symptoms misdiagnosed or dismissed. The study’s findings are a powerful reminder that menopause is not just a reproductive transition—it is a pivotal physiological period that profoundly impacts the entire cardiovascular system. This shift highlights a critical window where focused medical attention can make the greatest difference in long-term health outcomes.

Lifestyle strategies such as balanced nutrition, physical activity, stress reduction, and not smoking are important foundations for long-term health. For women experiencing menopausal symptoms, individualized treatment plans—whether lifestyle adjustments, medications, or hormone therapy—can play a role in overall well-being, including cardiovascular health.

What This Means for Women in Perimenopause and Menopause

This research serves as a call to action for women approaching and moving through menopause. The decline in estrogen is implicated as a major factor, potentially contributing to stiffer blood vessels, unfavorable shifts in cholesterol (e.g., higher LDL), and rising blood pressure. If you are in perimenopause or menopause, this means you should be proactive. Be sure to discuss a comprehensive heart health screening with your healthcare provider, including:

• Blood Pressure monitoring.
• Cholesterol Panel (lipids).
• Blood Sugar/Glucose levels.
• Body Mass Index (BMI) and Waist Circumference.

What This Means for Your Midlife Health

The accelerated risk post-menopause means that strategies focused on managing cardiovascular risk should begin before or immediately after the final menstrual period. This is not a time for passive waiting; it’s a time for active partnership with your doctor.

• Be Aware: Recognize that symptoms of heart attack can differ in women (e.g., nausea, extreme fatigue, or jaw pain, not just chest pain).
• Be Proactive: Establish heart-healthy habits, including balanced nutrition, regular physical activity, and stress reduction.
• Be Informed: If you are considering treatments for menopausal symptoms (like hot flashes), discuss the overall impact of treatments, including Hormone Therapy (HT), on your cardiovascular profile with your clinician.

Access & Availability

The recommended screenings (blood pressure, cholesterol, glucose) are widely available and routine during annual physicals and gynecological exams. Access to these preventative measures is high. For women seeking to understand their personalized risk better, new advanced lipid panels and genetic testing are increasingly available but may require specialist referral or may not be fully covered by insurance.

Next Steps/What to Watch For

For yourself:

• Schedule a Check-up: Talk to your doctor about your cardiovascular health goals now, not just your menopausal symptoms.
• Know Your Numbers: Memorize your current blood pressure, LDL cholesterol, and blood glucose results.
• Advocate for Yourself: If you feel heart-related symptoms, seek immediate medical attention and clearly state that you are a post-menopausal woman.

In the Research: We’ll be monitoring for follow-up studies that explore the optimal timing and dosage of therapies, including HT, to mitigate the post-menopausal cardiovascular risk surge.

Further Reading

For a deeper dive into how menopause impacts cardiovascular health, explore our article, Menopause, Heart Disease Risk & Women’s Cardiovascular Health and the The American College of Cardiology press release.

Groundbreaking Research Meets Skepticism: Can We End Menopause? Should We Even Try?

What Happened

Researchers are studying a procedure called ovarian tissue cryopreservation (OTC), where a small piece of ovarian tissue is removed, frozen, and later reimplanted to restore ovarian function. Originally developed for young cancer patients to preserve fertility, this approach is now being explored as a way to delay menopause.

Why It Matters

Menopause is driven by the natural decline of ovarian function. If scientists can “pause” the aging of ovarian tissue and later reintroduce it, women could potentially extend their fertile years and postpone menopause. That has major implications—not just for fertility, but also for long-term health risks tied to estrogen loss, such as osteoporosis, cardiovascular disease, and cognitive decline.

What This Means for Women in Perimenopause/Menopause

For women already in perimenopause or menopause, this research may not provide direct benefits today. But it highlights how the scientific conversation is expanding—menopause is no longer seen as an untouchable, inevitable milestone. Future generations may have more choices about when menopause begins, shifting how women approach midlife health planning.

Access & Availability

Right now, ovarian tissue cryopreservation is only available in select fertility clinics and primarily for women facing medical treatments that threaten ovarian function, like chemotherapy. Using it solely to delay menopause remains experimental and is not yet offered as a standard option.

Benefits & Risks

Potential benefits could include longer fertility, a later onset of menopause, and extended protection from estrogen-related conditions. However, risks include the invasiveness of the surgery, possible complications from reimplantation, and the unknowns of artificially extending ovarian hormone production, such as long-term cancer risks.

Next Steps / What to Watch For

Clinical research is still in early stages. Scientists are monitoring safety, long-term outcomes, and the broader ethical questions—such as whether delaying menopause might create new health challenges. Watch for updates from fertility research centers and women’s health conferences over the next few years.

What This Means for Your Midlife Health

Even though this option isn’t available to women already experiencing menopause, it signals a shift: menopause is becoming a subject of innovation, not inevitability. By following these developments, you can stay informed about how science is reshaping the conversation around women’s health and aging.

Further Reading

If you’re curious to dive deeper, check out these resources:

• Yale Research: Could Ovarian Tissue Freezing Stop Menopause in Its Tracks?
• Review: Emerging Science on Menopause Prevention and Longevity
• Exploring Hormonal Frontiers: What Researchers Are Learning About Ovarian Aging